Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice

• Published in: Toxicon X Vol. 12; p. 100083
• Main Authors: Abrahão Cunha, Thays Crosara, Gontijo Couto, Ana Claudia, Januzzi, Eduardo, Rosa Ferraz Gonçalves, Rafael Tardin, Silva, Graziella, Silva, Cassia Regina
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.11.2021; Elsevier
• Subjects: BoNT-A treatment; BOTOX; Migraine; Orofacial pain; Pain; Pain; Orofacial pain; BoNT-A treatment; Migraine; BOTOX
• ISSN: 2590-1710; 2590-1710
• DOI: 10.1016/j.toxcx.2021.100083

The use of botulinum neurotoxin-A (BoNT-A) is an alternative for the management of orofacial pain disorders. Although only Botox has labeled, there are other commercial brands available for use, among them: Dysport, Botulift, Prosigne, and Xeomin. The objective of the present study was to evaluate the possible differences in the antinociceptive effect evoked by different commercially available formulations of BoNT-A in an animal model of inflammatory orofacial pain induced by formalin injection. Male C57/BL6 mice (20–25 g) were submitted to the pre-treatment with five different commercial brands of BoNT-A (Botox, Botulift, Xeomin, Dysport, or Prosigne; with doses between 0.02 and 0.2 Units of Botulinum Toxin, in 20 μL of 0.9% saline) three days prior the 2% formalin injection. All injections were made subcutaneously into the right perinasal area. After formalin injections, nociceptive behaviors like rubbing the place of injection were quantified during the neurogenic (0–5 min) and inflammatory (15–30 min) phases. The treatment using Botox, Botulift, and Xeomin were able to induce antinociceptive effects in both phases of the formalin-induced pain animal model, however, Dysport and Prosigne reduced the response in neither of them. Our data suggest that the treatment using different formulations of BoNT-A is not similar in efficacy as analgesics when evaluated in formalin-induced orofacial pain in mice. [Display omitted] •Botulinum neurotoxin-a reduced formalin-induced orofacial pain in mice.•There are differences in the analgesic potential of different available commercial brands of botulinum neurotoxin-A.•Botox, Botulift, Xeomin demonstrated analgesic effect when evaluated in formalin-induced orofacial pain in mice.